Building virtual patients using simulation-based inference

In the context of <i>in silico</i> clinical trials, mechanistic computer models for pathophysiology and pharmacology (here Quantitative Systems Pharmacology models, QSP) can greatly support the decision making for drug candidates and elucidate the (potential) response of patients to existing and novel treatments. These models are built on disease mechanisms and then parametrized using (clinical study) data. Clinical variability among patients is represented by alternative model parameterizations, called virtual patients. Despite the complexity of disease modeling itself, using individual patient data to build these virtual patients is particularly challenging given the high-dimensional, potentially sparse and noisy clinical trial data. In this work, we investigate the applicability of simulation-based inference (SBI), an advanced probabilistic machine learning approach, for virtual patient generation from individual patient data and we develop and evaluate the concept of nearest patient fits (SBI NPF), which further enhances the fitting performance. At the example of rheumatoid arthritis where prediction of treatment response is notoriously difficult, our experiments demonstrate that the SBI approaches can capture large inter-patient variability in clinical data and can compete with standard fitting methods in the field. Moreover, since SBI learns a probability distribution over the virtual patient parametrization, it naturally provides the probability for alternative parametrizations. The learned distributions allow us to generate highly probable alternative virtual patient populations for rheumatoid arthritis, which could potentially enhance the assessment of drug candidates if used for <i>in silico</i> trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Systems Biology
Published
2024-09-12
DOI
https://doi.org/10.3389/fsysb.2024.1444912
Citations
3
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
2.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Building virtual patients using simulation-based inference

Clemens Giegerich, Nathalie Paul, Venetia Karamitsou, Alexander Kister et al.
3 citations
Frontiers in Systems Biology
Statistical Methods in Clinical Trials
2.13
article

Building virtual patients using simulation-based inference

Clemens Giegerich, Nathalie Paul, Venetia Karamitsou, Alexander Kister, Markus Rehberg, Afshin Sadeghi, Moritz Lücke, Britta Wagenhuber
article en
3 citations

Abstract

In the context of <i>in silico</i> clinical trials, mechanistic computer models for pathophysiology and pharmacology (here Quantitative Systems Pharmacology models, QSP) can greatly support the decision making for drug candidates and elucidate the (potential) response of patients to existing and novel treatments. These models are built on disease mechanisms and then parametrized using (clinical study) data. Clinical variability among patients is represented by alternative model parameterizations, called virtual patients. Despite the complexity of disease modeling itself, using individual patient data to build these virtual patients is particularly challenging given the high-dimensional, potentially sparse and noisy clinical trial data. In this work, we investigate the applicability of simulation-based inference (SBI), an advanced probabilistic machine learning approach, for virtual patient generation from individual patient data and we develop and evaluate the concept of nearest patient fits (SBI NPF), which further enhances the fitting performance. At the example of rheumatoid arthritis where prediction of treatment response is notoriously difficult, our experiments demonstrate that the SBI approaches can capture large inter-patient variability in clinical data and can compete with standard fitting methods in the field. Moreover, since SBI learns a probability distribution over the virtual patient parametrization, it naturally provides the probability for alternative parametrizations. The learned distributions allow us to generate highly probable alternative virtual patient populations for rheumatoid arthritis, which could potentially enhance the assessment of drug candidates if used for <i>in silico</i> trials.

Frontiers in Systems BiologyVol. 4
Federal Institute For Materials Research and Testing (DE), Sanofi (Germany) (DE), Fraunhofer Institute for Intelligent Analysis and Information Systems (DE)
Peace, Justice and strong institutions
Openalex Percentile: Top 12%
Statistical Methods in Clinical Trials
2.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.